Amgen

Amgen edged lower today by roughly 0.5%, reaching an intraday high of $370.38 before closing at $366.05. The pullback reflects multiple headwinds: Erste Group analysts recently trimmed earnings forecasts, while Merck's newly launched cholesterol therapy adds competitive pressure. Nevertheless, fundamentals remain resilient—Q1 EPS reached $3.34, up 4.38% YoY, and operating profit surged 24.43% YoY with net margins above 21%. Year-to-date the stock is up 11.72% and trades near its 52-week high of $391.29 (down 6.45%), well above both the 20-day and 60-day moving averages. However, valuations remain elevated at a PE of 25.3 and PB of 21.5, while analyst views remain mixed—Citi maintains a hold rating while Guggenheim stays constructive—suggesting ongoing debate over near-term momentum.

Amgen rose 0.6% to close at $366.24 today, with intraday range spanning $362.58 to $368.69, reflecting ongoing market debate between solid fundamentals and elevated valuation concerns. Q1 earnings demonstrated resilience, with operating income surging 24.43% YoY to $2.913 billion and EPS of $3.34 gaining 4.38% YoY. The recent settlement of shareholder litigation resolved a lingering overhang. However, recent analyst downgrades to earnings forecasts and Merck's breakthrough in the cholesterol-drug race signal intensifying competitive pressures in key markets. On valuation, the stock trades at 25.34x PE, posting 11.78% YTD gains with approximately 6.4% upside to the 52-week high of $391.29. Notably, operating margins expanded substantially, with Q1 net margin reaching 21.11% compared to 13.51% in Q4, signaling improved operational leverage.

Amgen started the day with modest pre-market gains but gave back the advance during the regular session. The stock surged to $370.29 at 09:31 ET before retreating steadily, closing down 0.58% at $364.17 with an intraday low of $363.83 at 15:30 ET. Erste Group Bank's recent downward revision of earnings estimates weighed on sentiment, while elevated valuation concerns—the stock trades at P/E 25.2—added pressure. Q1 EPS of $3.34 showed decelerating growth at just 4.38% year-over-year, a sharp slowdown from Q4's 112% jump. The stock remains above its 20-day moving average of $360.90 and has gained 11.15% year-to-date, though it sits 6.93% below its 52-week high of $391.29. While Guggenheim remains bullish on the company's oncology pipeline, near-term tension between profit-taking and valuation concerns dominates.

Amgen declined 1.6% to $366.29 as analysts adjusted outlooks, with Erste Group Bank trimming earnings estimates and Citi maintaining a cautious stance, signaling market reservations about growth prospects; Guggenheim's positive forecast provided partial offset. Q1 results showed revenue of $8.62 billion, up 5.76% year-over-year, and EPS of $3.34, up 4.38% year-over-year, though deceleration versus the prior quarter may amplify concerns about longer-term growth. The P/E of 25.3 remains reasonable. Year-to-date the stock is up 11.8% and trades roughly 6.4% below its 52-week peak, leaving upside room. Market sentiment on the valuation attractiveness of its oncology portfolio remains mixed.

Amgen shares advanced roughly 3.7% to $371.58 during regular trading hours today, with gains slightly trimmed to $369.51 in after-hours trading. The advance was supported by multiple positive catalysts: Guggenheim issued a positive forecast while a court blocked Colorado's price cap on Enbrel, the company's key immunology drug. On the earnings front, Q1 2026 showed solid fundamentals with EPS of $3.34 (up 4.38% YoY) and revenue of $8.618B (up 5.76% YoY), demonstrating robust net margins of 21.1%. The company's market capitalization stands at $200.5 billion with a PE ratio of 25.71. However, headwinds persist: a medical journal retracted a Tavneos clinical trial paper and Citigroup assigned only a hold rating, signaling market concerns on valuation and near-term direction.